Zogenix (NASDAQ:ZGNX) Posts Earnings Results, Misses Expectations By $5.70 EPS
Zogenix (NASDAQ:ZGNX) announced its quarterly earnings results on Thursday. The company reported ($6.75) EPS for the quarter, missing analysts’ consensus estimates of ($1.05) by ($5.70), Briefing.com reports. The firm had revenue of $0.63 million for the quarter, compared to analysts’ expectations of $0.39 million. During the same period in the previous year, the company earned ($1.08) EPS.
Shares of ZGNX traded down $0.68 on Friday, reaching $43.40. The company’s stock had a trading volume of 532,200 shares, compared to its average volume of 565,004. The company has a debt-to-equity ratio of 0.02, a current ratio of 7.19 and a quick ratio of 7.19. The stock has a market capitalization of $1.98 billion, a P/E ratio of -13.44 and a beta of 1.94. The stock’s 50 day simple moving average is $42.50 and its two-hundred day simple moving average is $43.03. Zogenix has a 12-month low of $33.43 and a 12-month high of $56.50.
In related news, EVP Gail M. Farfel sold 3,446 shares of the firm’s stock in a transaction that occurred on Thursday, August 22nd. The shares were sold at an average price of $52.00, for a total value of $179,192.00. Following the transaction, the executive vice president now owns 4,891 shares of the company’s stock, valued at $254,332. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 4.40% of the company’s stock.
Zogenix Company Profile
Zogenix, Inc, a pharmaceutical company, develops and commercializes therapies for the treatment of transformative central nervous system disorders in the United States. Its lead product candidate is the Fintepla/ZX008, a low-dose fenfluramine, which is in Phase III clinical trials for the treatment of seizures associated with Dravet syndrome.
Further Reading: Momentum Investing
Receive News & Ratings for Zogenix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zogenix and related companies with MarketBeat.com's FREE daily email newsletter.